Alx Oncology Company Leadership
| ALXO Stock | USD 1.31 0.15 10.27% |
About 79 percent of Alx Oncology's insiders are selling. The analysis of the overall insider sentiment regarding Alx Oncology Holdings suggests that quite a few insiders are terrified. Alx Oncology employs about 89 people. The company is managed by 19 executives with a total tenure of roughly 208 years, averaging almost 10.0 years of service per executive, having 4.68 employees per reported executive.
Alx Oncology's Insider Buying Vs Selling
21
Selling | Buying |
Latest Trades
| 2025-01-06 | Shelly Pinto | Disposed 2221 @ 1.8 | View | ||
| 2024-12-30 | Shelly Pinto | Disposed 1426 @ 1.58 | View | ||
| 2024-12-02 | Rekha Hemrajani | Acquired 30000 @ 1.55 | View | ||
| 2024-08-14 | Sophia Randolph | Disposed 1365 @ 2.58 | View | ||
| 2024-07-11 | Jaume Pons | Disposed 20000 @ 7.9 | View | ||
| 2024-07-05 | Shelly Pinto | Disposed 1823 @ 5.5 | View | ||
| 2024-07-01 | Sophia Randolph | Disposed 3273 @ 5.82 | View | ||
| 2024-06-13 | Peter S Garcia | Acquired 12000 @ 8.53 | View | ||
| 2024-06-04 | Jaume Pons | Disposed 20000 @ 8.43 | View | ||
| 2024-05-13 | Sophia Randolph | Disposed 12000 @ 15.94 | View | ||
| 2024-05-06 | Jaume Pons | Disposed 20000 @ 15.92 | View | ||
| 2024-04-16 | Jaume Pons | Disposed 50000 @ 14.2 | View | ||
| 2024-04-04 | Jaume Pons | Disposed 20000 @ 11.15 | View | ||
| 2024-03-14 | Jason Lettmann | Acquired 4400 @ 11.31 | View |
Monitoring Alx Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Alx |
Alx Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.4925) % which means that it has lost $0.4925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9894) %, meaning that it created substantial loss on money invested by shareholders. Alx Oncology's management efficiency ratios could be used to measure how well Alx Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to drop to -0.63. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Alx Oncology's Non Current Assets Total are very stable compared to the past year. As of the 31st of January 2025, Total Current Assets is likely to grow to about 234.8 M, while Total Assets are likely to drop about 254.3 M.As of the 31st of January 2025, Common Stock Shares Outstanding is likely to drop to about 40.8 M. In addition to that, Net Loss is likely to grow to about (105.6 M)
Alx Oncology Workforce Comparison
Alx Oncology Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,992. Alx Oncology holds roughly 89.0 in number of employees claiming about 2.97% of equities under Health Care industry.
Alx Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alx Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alx Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alx Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jaume Pons over a week ago Acquisition by Jaume Pons of 50000 shares of Alx Oncology at 1.65 subject to Rule 16b-3 | ||
Shelly Pinto over three weeks ago Disposition of 2221 shares by Shelly Pinto of Alx Oncology at 1.8 subject to Rule 16b-3 | ||
Jaume Pons over a month ago Disposition of 10796 shares by Jaume Pons of Alx Oncology at 1.5802 subject to Rule 16b-3 | ||
Jason Lettmann over a month ago Acquisition by Jason Lettmann of 200000 shares of Alx Oncology at 1.66 subject to Rule 16b-3 | ||
Sandler Alan B. over two months ago Acquisition by Sandler Alan B. of 600000 shares of Alx Oncology at 1.22 subject to Rule 16b-3 | ||
Jaume Pons over three months ago Acquisition by Jaume Pons of 25846 shares of Alx Oncology at 0.99 subject to Rule 16b-3 | ||
Randolph Sophia over three months ago Disposition of 1797 shares by Randolph Sophia of Alx Oncology at 16.6716 subject to Rule 16b-3 | ||
Shelly Pinto over three months ago Acquisition by Shelly Pinto of 36000 shares of Alx Oncology at 5.86 subject to Rule 16b-3 |
Alx Oncology Notable Stakeholders
An Alx Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alx Oncology often face trade-offs trying to please all of them. Alx Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alx Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jason Lettmann | CEO Director | Profile | |
| Venita Almeida | VP Development | Profile | |
| Lisa Sauer | Senior Assurance | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Christopher JD | General Counsel | Profile | |
| Shelly CPA | Interim Officer | Profile | |
| Corey Goodman | Independent Chairman | Profile | |
| Shelly Pinto | Senior Officer | Profile | |
| Caitlyn Doherty | Manager Communications | Profile | |
| Sue Naim | Senior Operations | Profile | |
| Michael Chang | Vice Operations | Profile | |
| MS MD | Senior Pharmacovigilance | Profile | |
| Sophia MD | Chief Director | Profile | |
| Harish CFA | Chief Officer | Profile | |
| Jaume Pons | President, Founder | Profile | |
| Jeanne Jew | Chief Officer | Profile | |
| Allison Dillon | Chief Officer | Profile | |
| Chris JD | G Counsel | Profile | |
| Athanasios MD | Senior Development | Profile |
About Alx Oncology Management Performance
The success or failure of an entity such as Alx Oncology Holdings often depends on how effective the management is. Alx Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.97) | (0.93) |
Alx Oncology Workforce Analysis
Traditionally, organizations such as Alx Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alx Oncology within its industry.Alx Oncology Manpower Efficiency
Return on Alx Oncology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 8.5M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 8M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.